rethinkTHC Search
Menu
Study breakdown

Teens treated for cannabis hyperemesis syndrome face dangerous heart rhythm risks from both the condition and its treatment

Case ReportPreliminary evidence
The takeaway

Two adolescent cases and a literature review reveal that cannabinoid hyperemesis syndrome combined with haloperidol treatment creates compounding risks for QTc prolongation and potentially fatal heart arrhythmias.

Emergency medicine physicians, pediatric providers, pharmacists, and cardiologists treating cannabinoid hyperemesis syndrome.

What the researchers found

A 15-year-old with CHS developed QTc prolongation to 528 msec with hypokalemia and hypomagnesemia during haloperidol treatment. A 17-year-old had borderline QTc prolongation (476 msec). Literature review identified five additional severe cases of QTc prolongation or Torsades de Pointes in adolescents and young adults treated for CHS.

Why it matters

Haloperidol is becoming a go-to treatment for CHS in emergency departments, but both cannabis itself and haloperidol independently prolong QTc. Combined with the electrolyte imbalances from vomiting, CHS patients face a triple threat to cardiac safety.

The numbers in context

Case 1: 15-year-old female, QTc 528 msec, hypokalemia and hypomagnesemia. Case 2: 17-year-old female, QTc 476 msec (borderline). Literature review: 5 additional severe cases including life-threatening TdP episodes.

How the study worked

Two case reports of adolescent CHS patients treated in the emergency department, supplemented by a systematic literature review through October 2024 for QTc prolongation and TdP cases in CHS treatment.

What this study cannot tell us

Case reports cannot establish incidence rates. Seven total cases across the literature may underrepresent or overrepresent the true risk. No controlled comparison of haloperidol versus alternative antiemetics for cardiac safety in CHS.

How to read the evidence

Case reports with literature review provide clinical alerts but cannot establish risk magnitude or comparative safety of treatment alternatives.

When this study was published

2024 publication with literature review through October 2024.

The bigger picture

As CHS cases surge with rising cannabis potency and use, emergency departments need protocols that account for the cardiac risks of treating a condition caused by a substance that itself affects the heart. Current standard practice may be creating avoidable cardiac emergencies.

Questions still open

  • Should EKG monitoring be mandatory before haloperidol administration in all CHS patients?
  • Are alternative antiemetics like ondansetron or fosaprepitant safer cardiac options for CHS?

Common questions

What is QTc prolongation?
A measurement on an EKG indicating the heart takes longer than normal to recharge between beats. When severely prolonged, it can trigger Torsades de Pointes, a life-threatening heart rhythm that can cause sudden cardiac death.
Why is haloperidol used for CHS?
Haloperidol has shown effectiveness against the severe nausea and vomiting of CHS when traditional antiemetics fail. However, it carries its own risk of QTc prolongation, which stacks on top of the cardiac effects of cannabis and electrolyte depletion from vomiting.

Read the original research

Mitigating the Risk of QTc Prolongation When Using Haloperidol for Acute Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents and Young Adults.

Journal of clinical medicine, 14(1)

Citation

Merino, Sandra; Tordera, Lissette; Jun, Allison; Yang, Sun. (2024). Mitigating the Risk of QTc Prolongation When Using Haloperidol for Acute Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents and Young Adults.. Journal of clinical medicine, 14(1). https://doi.org/10.3390/jcm14010163

Explore the wider topic